IDEAYA Biosciences, Inc. Research and Development Expense
IDEAYA Biosciences, Inc. (IDYA) reported Research and Development Expense of $108.69 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-04
- IDEAYA Biosciences, Inc. research and development expense for the quarter ending 2026-06-30 was $108.69M, a 46.43% increase year-over-year.
- IDEAYA Biosciences, Inc. research and development expense for the quarter ending 2026-03-31 was $95.73M, a 35.04% increase year-over-year.
- IDEAYA Biosciences, Inc. research and development expense for the quarter ending 2025-12-31 was $86.60M, a 38.22% decline year-over-year.
- IDEAYA Biosciences, Inc. research and development expense for the quarter ending 2025-09-30 was $82.99M, a 45.21% increase year-over-year.
- IDEAYA Biosciences, Inc. research and development expense for fiscal 2025 was $314.70M, a 6.80% increase from fiscal 2024.
- IDEAYA Biosciences, Inc. research and development expense for fiscal 2024 was $294.67M, a 127.53% increase from fiscal 2023.
- IDEAYA Biosciences, Inc. research and development expense for fiscal 2023 was $129.51M, a 44.64% increase from fiscal 2022.
- IDEAYA Biosciences, Inc. research and development expense for fiscal 2022 was $89.54M, a 53.95% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $108.69M 10-Q · filed 2026-08-04 | $204.41M 10-Q · filed 2026-08-04 | $291.01M derived: sum of 3 quarters · filed 2026-08-04 | $374.01M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $95.73M 10-Q · filed 2026-08-04 | $182.32M derived: sum of 2 quarters · filed 2026-08-04 | $265.32M derived: sum of 3 quarters · filed 2026-08-04 | $339.54M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $86.60M 10-Q · filed 2026-05-05 | $169.59M derived: sum of 2 quarters · filed 2026-05-05 | $243.82M derived: sum of 3 quarters · filed 2026-08-04 | $314.70M 10-K · filed 2026-02-17 |
| 2025-09-30 | $82.99M 10-Q · filed 2025-11-04 | $157.22M derived: sum of 2 quarters · filed 2026-08-04 | $228.10M 10-Q · filed 2025-11-04 | $368.29M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $74.23M 10-Q · filed 2026-08-04 | $145.11M 10-Q · filed 2026-08-04 | $285.30M derived: sum of 3 quarters · filed 2026-08-04 | $342.45M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $70.89M 10-Q · filed 2026-05-05 | $211.07M derived: sum of 2 quarters · filed 2026-05-05 | $268.22M derived: sum of 3 quarters · filed 2026-05-05 | $322.75M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $140.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $197.34M derived: sum of 2 quarters · filed 2026-02-17 | $251.87M derived: sum of 3 quarters · filed 2026-02-17 | $294.67M 10-K · filed 2026-02-17 |
| 2024-09-30 | $57.15M 10-Q · filed 2025-11-04 | $111.69M derived: sum of 2 quarters · filed 2025-11-04 | $154.49M 10-Q · filed 2025-11-04 | $193.26M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $54.53M 10-Q · filed 2025-08-05 | $97.34M 10-Q · filed 2025-08-05 | $136.11M derived: sum of 3 quarters · filed 2026-02-17 | $169.81M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $42.80M 10-Q · filed 2025-05-06 | $81.58M derived: sum of 2 quarters · filed 2026-02-17 | $115.28M derived: sum of 3 quarters · filed 2026-02-17 | $144.45M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $38.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $72.47M derived: sum of 2 quarters · filed 2026-02-17 | $101.65M derived: sum of 3 quarters · filed 2026-02-17 | $129.51M 10-K · filed 2026-02-17 |
| 2023-09-30 | $33.70M 10-Q · filed 2024-11-04 | $62.88M derived: sum of 2 quarters · filed 2024-11-04 | $90.74M 10-Q · filed 2024-11-04 | $115.45M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-06-30 | $29.18M 10-Q · filed 2024-08-06 | $57.04M 10-Q · filed 2024-08-06 | $81.75M derived: sum of 3 quarters · filed 2025-02-18 | $104.12M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-03-31 | $27.86M 10-Q · filed 2024-05-07 | $52.57M derived: sum of 2 quarters · filed 2025-02-18 | $74.94M derived: sum of 3 quarters · filed 2025-02-18 | $97.74M derived: sum of 4 quarters · filed 2025-02-18 |
| 2022-12-31 | $24.71M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $47.09M derived: sum of 2 quarters · filed 2025-02-18 | $69.88M derived: sum of 3 quarters · filed 2025-02-18 | $89.54M 10-K · filed 2025-02-18 |
| 2022-09-30 | $22.37M 10-Q · filed 2023-11-07 | $45.17M derived: sum of 2 quarters · filed 2023-11-07 | $64.82M 10-Q · filed 2023-11-07 | $80.93M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $22.80M 10-Q · filed 2023-08-10 | $42.45M 10-Q · filed 2023-08-10 | $58.56M derived: sum of 3 quarters · filed 2024-02-20 | $74.06M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $19.66M 10-Q · filed 2023-05-09 | $35.77M derived: sum of 2 quarters · filed 2024-02-20 | $51.27M derived: sum of 3 quarters · filed 2024-02-20 | $66.25M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $16.11M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $31.61M derived: sum of 2 quarters · filed 2024-02-20 | $46.59M derived: sum of 3 quarters · filed 2024-02-20 | $58.16M 10-K · filed 2024-02-20 |
| 2021-09-30 | $15.50M 10-Q · filed 2022-11-08 | $30.48M derived: sum of 2 quarters · filed 2022-11-08 | $42.05M 10-Q · filed 2022-11-08 | $54.10M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-06-30 | $14.98M 10-Q · filed 2022-08-15 | $26.55M 10-Q · filed 2022-08-15 | $38.60M derived: sum of 3 quarters · filed 2023-03-07 | $48.62M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-03-31 | $11.57M 10-Q · filed 2022-05-10 | $23.62M derived: sum of 2 quarters · filed 2023-03-07 | $33.64M derived: sum of 3 quarters · filed 2023-03-07 | $42.24M derived: sum of 4 quarters · filed 2023-03-07 |
| 2020-12-31 | $12.05M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $22.08M derived: sum of 2 quarters · filed 2023-03-07 | $30.67M derived: sum of 3 quarters · filed 2023-03-07 | $39.70M 10-K · filed 2023-03-07 |
| 2020-09-30 | $10.03M 10-Q · filed 2021-11-15 | $18.62M derived: sum of 2 quarters · filed 2021-11-15 | $27.65M 10-Q · filed 2021-11-15 | $36.19M derived: sum of 4 quarters · filed 2022-03-18 |
| 2020-06-30 | $8.60M 10-Q · filed 2021-08-10 | $17.62M 10-Q · filed 2021-08-10 | $26.16M derived: sum of 3 quarters · filed 2022-03-18 | $35.09M derived: sum of 4 quarters · filed 2022-03-18 |
| 2020-03-31 | $9.03M 10-Q · filed 2021-05-10 | $17.57M derived: sum of 2 quarters · filed 2022-03-18 | $26.49M derived: sum of 3 quarters · filed 2022-03-18 | $35.35M derived: sum of 4 quarters · filed 2022-03-18 |
| 2019-12-31 | $8.54M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $17.46M derived: sum of 2 quarters · filed 2022-03-18 | $26.32M derived: sum of 3 quarters · filed 2022-03-18 | $34.32M 10-K · filed 2022-03-18 |
| 2019-09-30 | $8.92M 10-Q · filed 2020-11-12 | $17.78M derived: sum of 2 quarters · filed 2020-11-12 | $25.78M 10-Q · filed 2020-11-12 | $33.35M derived: sum of 4 quarters · filed 2021-03-23 |
| 2019-06-30 | $8.86M 10-Q · filed 2020-08-12 | $16.86M 10-Q · filed 2020-08-12 | $24.43M derived: sum of 3 quarters · filed 2021-03-23 | $36.97M derived: sum of 4 quarters · filed 2021-03-23 |
| 2019-03-31 | $8.00M 10-Q · filed 2020-05-12 | $15.57M derived: sum of 2 quarters · filed 2021-03-23 | $28.11M derived: sum of 3 quarters · filed 2021-03-23 | $34.54M derived: sum of 4 quarters · filed 2021-03-23 |
| 2018-12-31 | $7.58M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | $20.11M derived: sum of 2 quarters · filed 2021-03-23 | $26.55M derived: sum of 3 quarters · filed 2021-03-23 | $31.75M 10-K · filed 2021-03-23 |
| 2018-09-30 | $12.54M 10-Q · filed 2019-11-13 | $18.97M derived: sum of 2 quarters · filed 2019-11-13 | $24.17M 10-Q · filed 2019-11-13 | |
| 2018-06-30 | $6.43M 10-Q · filed 2019-08-12 | $11.63M 10-Q · filed 2019-08-12 | ||
| 2017-12-31 | $12.38M 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |